Global Hydronephrosis Market – Industry Trends and Forecast to 2031

Análise e dimensão do mercado de hidronefrose

O mercado global de hidronefrose está a experimentar um crescimento impulsionado pela crescente consciencialização, pelos avanços na tecnologia médica e pelo aumento da incidência de obstruções do trato urinário. A hidronefrose, caracterizada por inchaço nos rins devido à acumulação de urina, afeta um número significativo de indivíduos em todo o mundo, com causas variadas, incluindo cálculos renais , tumores ou anomalias congénitas. A expansão do mercado é também impulsionada por inovações de diagnóstico, como a ecografia, a tomografia computorizada e a ressonância magnética, facilitando a deteção precoce e o planeamento do tratamento. Além disso, intervenções cirúrgicas como o implante de stent ureteral e a nefrostomia são tratamentos essenciais, garantindo o alívio dos sintomas e preservando a função renal.

O tamanho do mercado global de hidronefrose foi avaliado em 3,22 mil milhões de dólares em 2023 e deverá atingir os 6,72 mil milhões de dólares até 2031, com um CAGR de 9,64% durante o período de previsão de 2024 a 2031. Para além dos insights sobre cenários de mercado, tais como valor de mercado , taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research também incluem análises especializadas aprofundadas, epidemiologia de pacientes, análise de pipeline, análise de preços e a estrutura regulatória.

Âmbito do relatório e segmentação de mercado       

Definição de mercado

A hidronefrose é uma condição médica caracterizada pelo inchaço ou dilatação de um ou ambos os rins devido à acumulação de urina. Isto ocorre quando existe uma obstrução ou bloqueio no trato urinário, impedindo que a urina seja drenada adequadamente do rim para a bexiga. A obstrução pode ser causada por vários fatores, como cálculos renais, anomalias congénitas, tumores ou cicatrizes de infeções anteriores.   

Dinâmica do mercado da hidronefrose

Motoristas

• Aumento da prevalência de hidronefrose   

A prevalência da hidronefrose está a aumentar constantemente em todo o mundo, principalmente devido ao aumento da incidência de obstruções do trato urinário e de vários distúrbios renais. Fatores como cálculos renais, tumores, anomalias congénitas e infeções contribuem significativamente para o desenvolvimento da hidronefrose. A condição afeta indivíduos de todas as idades, mas é particularmente prevalente entre adultos e idosos. À medida que os estilos de vida evoluem, os hábitos alimentares mudam e as condições crónicas como a diabetes e a hipertensão se tornam mais generalizadas, os fatores de risco para complicações do trato urinário e distúrbios relacionados com os rins aumentam, impulsionando o crescimento do mercado.  

• Crescente população geriátrica propensa a doenças relacionadas com os rins  

A mudança demográfica global no sentido de uma população envelhecida levou a uma maior suscetibilidade a doenças relacionadas com os rins, incluindo a hidronefrose. Os idosos apresentam frequentemente alterações fisiológicas que afetam a função renal, como a diminuição do fluxo sanguíneo renal e a diminuição da capacidade de concentração da urina. Estes fatores, aliados à prevalência de doenças crónicas como a diabetes e a hipertensão entre os idosos, contribuem para o aumento da incidência de hidronefrose. À medida que a população idosa continua a crescer, os prestadores de cuidados de saúde enfrentam maiores exigências na gestão e tratamento eficaz das condições relacionadas com os rins, impulsionando o crescimento do mercado.

Oportunidades

• Aumento das despesas com a saúde     

Os recentes avanços no tratamento da hidronefrose revolucionaram os cuidados prestados aos doentes, oferecendo opções de gestão mais eficazes e menos invasivas. Procedimentos cirúrgicos minimamente invasivos, como o implante de stent ureteral e a nefrostomia, tornaram-se prática padrão no alívio das obstruções do trato urinário e na restauração da função renal. Estes procedimentos não só reduzem o tempo de recuperação e as admissões hospitalares, como também minimizam o risco de complicações em comparação com as cirurgias abertas tradicionais. Além disso, as terapêuticas farmacêuticas destinadas a abordar as causas subjacentes da hidronefrose, tais como medicamentos para dissolver pedras nos rins ou gerir infeções, melhoraram significativamente os resultados dos doentes, criando oportunidades para o crescimento do mercado. 

• Avanços nas opções de tratamento para a hidronefrose     

The global rise in healthcare expenditure reflects increasing investments in infrastructure, technology, and patient care, which are pivotal in addressing complex medical conditions like hydronephrosis. Governments and private sectors are allocating substantial resources towards improving healthcare accessibility and quality, particularly in developing regions where infrastructure gaps exist. This surge in funding supports the expansion of healthcare facilities, procurement of advanced medical equipment, and training of healthcare professionals specializing in kidney-related disorders. In addition, higher healthcare spending fosters research and development initiatives aimed at discovering innovative treatments and diagnostic tools for hydronephrosis.  These are creating significant market opportunities, reducing the burden of kidney-related diseases on individuals and societies alike.

Restraints/Challenges

• Adverse Effects of Medications and Surgical Interventions 

While advancements in hydronephrosis treatment offer significant benefits, they also come with potential risks and side effects that patients and healthcare providers must consider. Medications prescribed for managing kidney stones or infections may cause adverse reactions such as gastrointestinal upset or allergic responses in some individuals. Similarly, surgical interventions like ureteral stenting or nephrostomy carry risks of complications such as infection, bleeding, or damage to surrounding tissues. These potential side effects underscore the importance of thorough risk assessment and patient counselling before initiating treatment.  

• Regulatory Requirements for New Medical Devices and Treatments        

Navigating the regulatory landscape presents significant challenges for companies developing new medical devices and treatments for hydronephrosis. Stringent regulatory requirements, varying across different regions and countries, necessitate extensive clinical trials, safety evaluations, and documentation to obtain approvals. These processes aim to ensure the efficacy, safety, and quality of healthcare products before they reach the market and are used in patient care. However, the lengthy approval timelines and resource-intensive nature of regulatory compliance can pose barriers to innovation and market entry for smaller companies or start-ups.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In August 2023, Novartis announced the successful acquisition of Chinook Therapeutics, Inc., a biopharmaceutical company headquartered in Seattle, WA. Chinook Therapeutics specializes in the research, development, and commercialization of precision medicines targeting kidney diseases

Hydronephrosis Market Scope

The market is segmented on the basis of indication, treatment, type, and diagnosis. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

• Intrinsic
  • Acute Unilateral Obstructive Uropathy
  • Kidney Stone
  • Bladder Cancer
  • Bladder Stones
  • Cystocele
  • Urethral Stricture
  • Urethral Cancer
  • Others
• Extrinsic
  • Retroperitoneal Fibrosis
  • Ovarian Vein Syndrome
  • Cancer of the Cervix
  • Cancer of the Prostate
  • Uterine Prolapse
  • Prostate Cancer
  • Pregnancy
  • Others

Treatment

• Shock Wave Lithotripsy
• Laparoscopy
• Bladder Catheterization
• Steroid Therapy
• Others

Type

• Unilateral Hydronephrosis
• Bilateral Hydronephrosis

Diagnosis

• Laboratory Test
  • Urinalysis
  • Complete Blood Count
  • Electrolyte Analysis
  • Others
• Imaging
  • CT Scan Ultrasound
  • Intravenous
  • Pyelography
  • KUB X-Rays
  • Others

Hydronephrosis Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by country, indication, treatment, type, and diagnosis as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.

North America is expected to dominate the market due to increased expenditure on research and development, substantial healthcare spending, a higher prevalence of kidney-related disorders, the presence of key market players, and the introduction of technologically advanced products in these regions.   

Asia-Pacific is expected to witness significant growth during the forecast period due to rising government expenditure on the healthcare sector, an increasing geriatric population, especially in emerging economies like India and China, and rising personal disposable income. 

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Hydronephrosis Market Share Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the market are:

• Allergan (Ireland)
• Amgen Inc. (U.S.)
• Sanofi (France)
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Boston Scientific Corporation (U.S.)
• B. Braun Melsungen AG (Germany)
• Stryker (U.S.)
• Zimmer Biomet (U.S.)
• Smith & Nephew plc (U.K.)
• Promega Corporation (U.S.)
• Sigma-Aldrich Co. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)

SKU-13210